



TITLE:

S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial

AUTHOR(S):

Yamada, Y; Denda, T; Gamoh, M; Iwanaga, I; Yuki, S; Shimodaira, H; Nakamura, M; ... Takahashi, S; Komatsu, Y; Ishioka, C

---

CITATION:

Yamada, Y ...[et al]. S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial. *Annals of Oncology* 2018, 29(3): 624-631

ISSUE DATE:

2018-03-01

URL:

<http://hdl.handle.net/2433/231092>

RIGHT:

© The Author(s) 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact [journals.permissions@oup.com](mailto:journals.permissions@oup.com)

## ORIGINAL ARTICLE

# S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial

Y. Yamada<sup>1†</sup>, T. Denda<sup>2</sup>, M. Gamoh<sup>3</sup>, I. Iwanaga<sup>4</sup>, S. Yuki<sup>5</sup>, H. Shimodaira<sup>6</sup>, M. Nakamura<sup>7</sup>, T. Yamaguchi<sup>8</sup>, H. Ohori<sup>9</sup>, K. Kobayashi<sup>10</sup>, M. Tsuda<sup>11</sup>, Y. Kobayashi<sup>12</sup>, Y. Miyamoto<sup>13</sup>, M. Kotake<sup>14</sup>, K. Shimada<sup>15</sup>, A. Sato<sup>16</sup>, S. Morita<sup>17</sup>, S. Takahashi<sup>6</sup>, Y. Komatsu<sup>18\*</sup> & C. Ishioka<sup>6</sup>

<sup>1</sup>Gastrointestinal Medical Oncology Division, National Cancer Center Hospital, Tokyo; <sup>2</sup>Division of Gastroenterology, Chiba Cancer Center, Chiba; <sup>3</sup>Department of Medical Oncology, Osaka Citizen Hospital, Miyagi; <sup>4</sup>Department of Medical Oncology, Japanese Red Cross Kitami Hospital, Hokkaido; <sup>5</sup>Department of Gastroenterology and Hepatology, Hokkaido University Hospital, Hokkaido; <sup>6</sup>Department of Medical Oncology, Tohoku University Hospital, Miyagi; <sup>7</sup>Comprehensive Cancer Center, Aizawa Hospital, Nagano; <sup>8</sup>Department of Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo; <sup>9</sup>Clinical Oncology, Japanese Red Cross Ishinomaki Hospital, Miyagi; <sup>10</sup>Division of Medical Oncology, Showa University Northern Yokohama Hospital, Kanagawa; <sup>11</sup>Department of Gastroenterological Oncology, Hyogo Cancer Center, Hyogo; <sup>12</sup>Department of Internal Medicine, Kushiro Rosai Hospital, Hokkaido; <sup>13</sup>Department of Gastroenterological Surgery, Kumamoto University, Kumamoto; <sup>14</sup>Department of Surgery, Kouseiren Takaoka Hospital, Toyama; <sup>15</sup>Department of Internal Medicine, Showa University Koto Toyosu Hospital, Tokyo; <sup>16</sup>Department of Medical Oncology, Hirosaki University Graduate School of Medicine, Aomori; <sup>17</sup>Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto; <sup>18</sup>Department of Cancer Chemotherapy, Hokkaido University Hospital Cancer Center, Hokkaido, Japan

\*Correspondence to: Dr Yoshito Komatsu, Department of Cancer Chemotherapy, Hokkaido University Hospital, Kita-15 Nishi-7 Kita-ku, Sapporo City 060-8638, Japan. Tel: +81-706-5657; E-mail: ykomatsu@ac.cyberhome.ne.jp

†Present address: Department of Clinical Oncology, Hamamatsu University, Shizuoka and Department of Oncology, National Center for Global Health and Medicine, Tokyo, Japan.

**Background:** Combination therapy with oral fluoropyrimidine and irinotecan has not yet been established as first-line treatment of metastatic colorectal cancer (mCRC). We carried out a randomized, open-label, phase III trial to determine whether S-1 and irinotecan plus bevacizumab is noninferior to mFOLFOX6 or CapeOX plus bevacizumab in terms of progression-free survival (PFS).

**Patients and methods:** Patients from 53 institutions who had previously untreated mCRC were randomly assigned (1 : 1) to receive either mFOLFOX6 or CapeOX plus bevacizumab (control group) or S-1 and irinotecan plus bevacizumab (experimental group); a 3-week regimen: intravenous infusions of irinotecan 150 mg/m<sup>2</sup> and bevacizumab 7.5 mg/kg on day 1, oral S-1 80 mg/m<sup>2</sup> twice daily for 2 weeks, followed by a 1-week rest; or a 4-week regimen: irinotecan 100 mg/m<sup>2</sup> and bevacizumab 5 mg/kg on days 1 and 15, S-1 80 mg/m<sup>2</sup> twice daily for 2 weeks, followed by a 2-week rest). The primary end point was PFS. The noninferiority margin was 1.25; noninferiority would be established if the upper limit of the 95% confidence interval (CI) for the hazard ratio (HR) of the control group versus the experimental group was less than this margin.

**Result:** Between June 2012 and September 2014, 487 patients underwent randomization. Two hundred and forty-three patients assigned to the control group and 241 assigned to the experimental group were included in the primary analysis. Median PFS was 10.8 months (95% CI 9.6–11.6) in the control group and 14.0 months (95% CI 12.4–15.5) in the experimental group (HR 0.84, 95% CI 0.70–1.02; *P* < 0.0001 for noninferiority, *P* = 0.0815 for superiority). One hundred and fifty-seven patients (64.9%) in the control group and 140 (58.6%) in the experimental group had adverse events of grade 3 or higher.

**Conclusion:** S-1 and irinotecan plus bevacizumab is noninferior to mFOLFOX6 or CapeOX plus bevacizumab with respect to PFS as first-line treatment of mCRC and could be a new standard treatment.

**Clinical trials number:** UMIN000007834

**Key words:** IRIS, SIRB, FOLFOX, XELOX, mCRC

## Introduction

FOLFOX, CapeOX, or FOLFIRI plus bevacizumab are extensively used as first-line treatment of metastatic colorectal cancer (mCRC) [1, 2]. Oxaliplatin-based combination regimens such as FOLFOX and CapeOX are commonly used in general clinical practice in many countries, including Japan and the United States, in preference to FOLFIRI, because the resulting alopecia and gastrointestinal toxicity are milder. However, peripheral neuropathy induced by oxaliplatin often leads to treatment withdrawal, negatively affecting treatment continuity. Furthermore, peripheral neuropathy is usually prolonged, interfering with the daily lives of patients and reducing their quality of life (QOL) [1, 3]. Meanwhile, combination therapy with an oral fluoropyrimidine and irinotecan as first-line treatment of mCRC has not yet been established [4].

The oral fluoropyrimidine S-1 has been approved in Japan; the European Medicines Agency has approved S-1 for gastric cancer. S-1 is a combined preparation consisting of tegafur, a prodrug of 5-fluorouracil (5-FU), and the modulators gimeracil and oteracil potassium [5]. S-1 plus irinotecan was shown to be noninferior to FOLFIRI as second-line chemotherapy for mCRC [6, 7]. Two phase II studies have evaluated 3-week and 4-week regimens of S-1 combined with irinotecan plus bevacizumab as first-line chemotherapy for mCRC; promising outcomes were obtained [8, 9].

On the basis of these studies, we examined whether S-1 and irinotecan plus bevacizumab was noninferior in terms of progression-free survival (PFS) to mFOLFOX6 or CapeOX plus bevacizumab as first-line chemotherapy for mCRC.

## Methods

### Study design

The TRICOLORE trial was an open-label, multicenter, randomized phase III trial conducted in Japan in patients who previously untreated mCRC. This study was conducted in accordance with the ethical principles of the Declaration of Helsinki and complied with the Japanese ethical guidelines for clinical studies. The study was approved by the institutional review board of each participating institution.

### Participants

The main inclusion criteria were as follows: histologically confirmed colorectal adenocarcinoma; unresectable mCRC; age 20 years or older; ECOG performance status of 0 or 1; no previous chemotherapy or radiotherapy; adequate oral intake; and adequate organ function. The main exclusion criteria were as follows: sensory neuropathy; serious diarrhea; gastrointestinal obstruction; symptomatic peritoneal metastasis; and a history of gastrointestinal perforation within the 6 months before enrollment. All patients provided written informed consent before enrollment. The details of the criteria have been reported previously [10].

### Randomization and masking

Participants were randomly assigned (1 : 1) to receive either mFOLFOX6 or CapeOX plus bevacizumab (control group) or to receive either a 3-week or a 4-week regimen of S-1 and irinotecan plus bevacizumab (experimental group). Each participating institution could select either mFOLFOX6 plus bevacizumab or CapeOX plus bevacizumab and either a 3-week or 4-week regimen of S-1 and irinotecan plus bevacizumab. After reporting to the data center (AC Medical Inc., Tokyo, Japan), patient enrollment was initiated (supplementary Figure S1, available at *Annals of Oncology* online). Randomization was performed centrally using the minimization method with the following stratification factors: institution; adjuvant chemotherapy (none, including oxaliplatin, or not including oxaliplatin); and the number of metastatic organs (0 or 1 versus  $\geq 2$ ).

### Procedures

The mFOLFOX6 plus bevacizumab regimen consisted of bevacizumab (5 mg/kg) given as an intravenous infusion on day 1 of each 2-week cycle, followed by a simultaneous intravenous infusion of oxaliplatin (85 mg/m<sup>2</sup>) plus l-leucovorin (200 mg/m<sup>2</sup>), an intravenous bolus 5-FU (400 mg/m<sup>2</sup>), and a continuous intravenous infusion of 5-FU (2400 mg/m<sup>2</sup>). The CapeOX plus bevacizumab regimen consisted of bevacizumab (7.5 mg/kg) given as an intravenous infusion on day 1 of each 3-week cycle, followed by an intravenous infusion of oxaliplatin (130 mg/m<sup>2</sup>). Capecitabine (1000 mg/m<sup>2</sup>) was taken orally twice daily, from after dinner on day 1 to after breakfast on day 15, followed by a 7-day rest. The 3-week S-1 and irinotecan plus bevacizumab regimen consisted of bevacizumab (7.5 mg/kg) given as an intravenous infusion on day 1 of each 3-week cycle, followed by an intravenous infusion of irinotecan (150 mg/m<sup>2</sup>). S-1 (40 mg/m<sup>2</sup>) was taken orally twice daily, from after dinner on day 1 to after breakfast on day 15, followed by a 7-day rest. The 4-week S-1 and irinotecan plus bevacizumab regimen consisted of bevacizumab (5 mg/kg) given as an intravenous infusion on day 1 and day 15 of each 4-week cycle, followed by an intravenous infusion of irinotecan (100 mg/m<sup>2</sup>). S-1 (40 mg/m<sup>2</sup>) was taken orally twice daily, from after dinner on day 1 to after breakfast on day 15, followed by a 14-day rest. Cycles were repeated for each patient until criteria for withdrawal of the study treatment were met. For the mFOLFOX6 plus bevacizumab and CapeOX plus bevacizumab regimens, oxaliplatin-induced sensory neuropathy was taken into consideration, and treatment could be skipped if patients had received at least 600 mg/m<sup>2</sup> of oxaliplatin overall. The details of dose modifications have been reported previously [10].

Tumor assessment by means of diagnostic imaging was carried out every 8 weeks, and tumor responses were assessed according to RECIST version 1.1. Observed adverse events were evaluated according to CTCAE v4.0. QOL was assessed according to FACT-C TOI scale and FACT/GOG-Ntx scale before the start of treatment and at 16 and 24 weeks.

### Outcomes

The primary end point was PFS, defined as the period from the date of enrollment to the date of disease progression or of death from any cause without progression, whichever came first. Secondary end points were overall survival, time to treatment failure (TTF), response rate, adverse events, QOL, quality-adjusted life years (QALYs), cost-effectiveness, and biomarker analysis.

## Statistical analysis

On the basis of the results of previous studies, the median PFS was estimated to be 11 months for the control group and 12 months for the experimental group [hazard ratio (HR), 0.917]. Given that the permissible limit for the HR was 1.25, with a statistical power of 85%, an alpha level of 0.025 (one-sided), an enrollment period of 36 months, and a follow-up period of 18 months for the primary end point of PFS, we estimated that 434 patients would be required (required number of events, 374). To compensate for ineligible patients, the target number of patients was set at 450. Thus, noninferiority would be established if the upper limit of the 95% confidence interval (CI) for the HR of the control group versus the experimental group was  $<1.25$ . If noninferiority was demonstrated in the study, superiority would be tested. The primary analysis was conducted using the full analysis set on an intention-to-treat basis.

We estimated time-dependent events using the Kaplan–Meier method. We calculated HRs and their CIs with Cox proportional-hazards models and adjusted for stratification factors (excluding institutions) and treatment groups as covariates. Patients who received at least one dose of the assigned study drugs were included in the analyses of dose intensity and safety. QOL analysis was conducted using data from patients in the safety analysis population for whom the pretreatment QOL could be evaluated.

All statistical analyses were carried out using SAS, version 9.4 (SAS Institute, Cary, NC). This trial is registered with UMIN-CTR (<http://www.umin.ac.jp/ctr/>) (000007834).

## Results

From 1 June 2012 through 16 September 2014, 487 patients from 53 institutions were randomly assigned, 244 patients to the control group and 243 patients to the experimental group (supplementary Figure S2, available at *Annals of Oncology* online). Two patients who were confirmed to have no colorectal adenocarcinoma after randomization and one patient who withdrew consent were excluded from the primary analysis. The cut-off date for primary analysis of the primary end point was 30 April 2016. Demographic characteristics were similar in both groups (Table 1).

The median follow-up period was 32.4 months (range 1.5–46.6). During this period, PFS events occurred in 426 (88%) of 484 patients. While the median PFS was 10.8 months (95% CI 9.6–11.6) in the control group, it was 14.0 months (95% CI 12.4–15.5) in the experimental group (HR 0.84, 95% CI 0.70–1.02). The upper limit of the HR for PFS was lower than the prespecified noninferiority margin of 1.25 ( $P < 0.0001$  for noninferiority,  $P = 0.0815$  for superiority; Figure 1A). The details of PFS for each chemotherapy regimen are given in supplementary Figure S3, available at *Annals of Oncology* online. In the subgroup analysis of PFS, significant interactions were observed between the allocated groups and age (supplementary Figure S4, available at *Annals of Oncology* online). Median TTF in the control group and the experimental group was 7.7 months (95% CI 7.1–8.2) and 9.6 months (95% CI 8.2–11.0), respectively (HR 0.71, 95% CI 0.59–0.85,  $P = 0.0002$ ; Figure 1B). Treatment status in each group is presented in supplementary Table S1, available at *Annals of Oncology* online. The response rate of target lesions was 70.6% in the control group and 66.4% in the experimental group ( $P = 0.34$ ; supplementary Table S2, available at *Annals of Oncology* online). The curative resection rate was 8.6% in the control group and 12.4% in the experimental group ( $P = 0.17$ ). Overall survival analysis was conducted on the basis of 218 deaths

(45%) among 484 patients. The median survival time in the control group and the experimental group was 33.6 months (95% CI 29.8–40.1) and 34.9 months (95% CI 31.9–42.4), respectively (HR 0.86, 95% CI 0.66–1.13,  $P = 0.2841$ ; Figure 1C).

Adverse events are summarized in Table 2. The incidences of grade 3 or higher leukopenia, neutropenia, febrile neutropenia, thromboembolism, and diarrhea were significantly higher in the experimental group than in the control group. In post hoc analyses, the incidences of grade 3 or higher diarrhea in patients with a creatinine clearance (CCr) of 70 ml/min or higher and patients with a CCr of  $<70$  ml/min at enrollment were, respectively, 6.7% and 6.5% in the control group as compared with 11.5% and 19.6% in the experimental group. The incidences of grade 3 or higher sensory neuropathy, hand–foot syndrome, and paralytic ileus were significantly higher in patients receiving the control treatment than in those receiving the experimental treatment. Further information on the types of adverse events occurring in each treatment regimen is given in supplementary Table S3, available at *Annals of Oncology* online. There was one treatment-related death among patients given the CapeOX regimen and four treatment-related deaths among patients given the S-1 and irinotecan plus bevacizumab regimen.

Before treatment, 436 (90.6%) patients completed the QOL questionnaire. There was no statistically significant difference in the FACT-C TOI score trends over time between the control group and the experimental group ( $P = 0.74$ ; Figure 2A). However, the FACT/GOG-Ntx scores showed a significantly more favorable trend over time in the experimental group ( $P < 0.01$ ; Figure 2B).

The number of patients in whom the study treatment was discontinued by the data cut-off date was 235 in the control group and 226 in the experimental group. Among the patients whose study treatment was discontinued, second-line treatment was given to 206 patients (87.7%) in the control group and 198 patients (87.6%) in the experimental group. Oxaliplatin, irinotecan, bevacizumab, and EGFR antibodies were, respectively, administered to 12 (5.8%), 125 (60.7%), 111 (53.9%), and 26 (12.6%) patients in the control group and 112 (56.6%), 22 (11.1%), 106 (53.5%), and 20 (10.1%) patients in the experimental group. In addition, 106 (53.5%) patients in the experimental group were given an oral fluoropyrimidine.

A more detailed analysis of QOL will be reported separately. QALY, cost-effectiveness, and biomarker analysis will be reported after the conclusion of follow-up in September 2017.

## Discussion

To the best of our knowledge, the TRICOLORE trial is the first randomized phase III study to demonstrate the effectiveness of combination therapy with an oral fluoropyrimidine and irinotecan as first-line treatment of mCRC. In this study, we established the noninferiority of S-1 and irinotecan plus bevacizumab in terms of PFS to the standard regimen of mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment of mCRC. Although superiority could not be proven, the median PFS was 3.2 months longer in the experimental group than in the control group (HR 0.84, 95% CI 0.69–1.01), and the QOL results were favorable. In addition, S-1 and irinotecan plus bevacizumab prolonged

**Table 1. Baseline characteristics**

	mFOLFOX6 or CapeOX plus bevacizumab (n = 243)		S-1 and irinotecan plus bevacizumab (n = 241)	
	n	(%)	n	(%)
Sex				
Male	143	(58.8)	151	(62.7)
Female	100	(41.2)	90	(37.3)
PS (ECOG)				
0	205	(84.4)	204	(84.6)
1	38	(15.6)	37	(15.4)
Age				
Median [range]	65 [29–85]		64 [22–87]	
≥65	134	(55.1)	118	(49.0)
CCr at enrollment				
Median [range]	80.9 [60.0–153.1]		82.7 [60.0–182.8]	
≥70	181	(74.5)	185	(76.8)
Complications				
Yes	107	(44.0)	108	(44.8)
No	136	(56.0)	133	(52.2)
Adjuvant chemotherapy for colorectal cancer				
Yes	31	(12.8)	32	(13.3)
No	212	(87.2)	209	(86.7)
Differentiation assessed by histology				
Well or moderate	212	(87.2)	209	(86.7)
Poorly	14	(5.8)	14	(5.8)
Other	17	(7.0)	18	(7.5)
Primary lesion				
Colon	122	(50.2)	130	(53.9)
Rectosigmoid	39	(16.0)	32	(13.3)
Rectum	82	(33.7)	79	(32.8)
Primary lesion resection				
Yes	164	(67.5)	156	(64.7)
No	79	(32.5)	85	(35.3)
Metastatic organs				
0–1	124	(51.0)	127	(52.7)
≥2	119	(49.0)	114	(47.3)
Target lesion				
Yes	221	(90.9)	214	(88.8)
No	22	(9.1)	27	(11.2)
RAS status				
Wild type	99	(40.7)	105	(43.6)
Mutant type	65	(26.7)	58	(24.1)
Not definable	6	(2.5)	3	(1.2)
Missing data	73	(30.0)	75	(31.1)


CCr, creatinine clearance.

median TTF by 1.9 months (HR 0.71, 95% CI 0.59–0.85), with statistical significance.

The incidences of adverse events associated with each regimen were similar to the results of previous studies [2, 8, 9]. The incidence of grade 3 or higher diarrhea (13.4%) in the S-1 and irinotecan plus bevacizumab group was similar to that previously reported for first-line treatment with FOLFIRI plus bevacizumab (approximately 10%–14%), which was considered to demonstrate its tolerability [11, 12]. In patients with reduced renal

function, the clearance of gimeracil in S-1 is decreased, causing an increase in the blood concentration of FU as well as an increased incidence of related adverse reactions. In our study, in patients given S-1 and irinotecan plus bevacizumab whose CCr was <70 ml/min at enrollment, the incidence of grade 3 or higher diarrhea was 19.6%, which was higher than the incidence in patients whose CCr was 70 ml/min or higher (11.5%). UGT1A1 gene polymorphism, one of the risk factors for irinotecan-induced serious adverse reactions, was not assessed in our study;





**Figure 1.** Kaplan–Meier curves for (A) progression-free survival, (B) time to treatment failure, and (C) overall survival.

Table 2. Adverse events

	mFOLFOX6 or CapeOX plus bevacizumab (n = 242)				S-1 and irinotecan plus bevacizumab (n = 239)				P value
	Any		≥Grade 3		Any		≥Grade 3		
	n	(%)	n	(%)	n	(%)	n	(%)	
Patients with at least 1 AE	242	(100.0)	157	(64.9)	236	(98.7)	140	(58.6)	0.16
Laboratory findings									
Leukopenia	154	(63.6)	6	(2.5)	157	(65.7)	21	(8.8)	<0.01
Neutropenia	139	(57.4)	33	(13.6)	150	(62.8)	58	(24.3)	<0.01
Thrombocytopenia	151	(62.4)	4	(1.7)	74	(31.0)	2	(0.8)	0.69
Anemia	92	(38.0)	5	(2.1)	121	(50.6)	12	(5.0)	0.09
Bilirubin	80	(33.1)	6	(2.5)	104	(43.5)	8	(3.3)	0.60
AST	119	(49.2)	8	(3.3)	80	(33.5)	5	(2.1)	0.58
ALT	82	(33.9)	6	(2.5)	84	(35.1)	5	(2.1)	1.00
Creatinine	30	(12.4)	2	(0.8)	30	(12.6)	2	(0.8)	1.00
Proteinuria	107	(44.2)	7	(2.9)	103	(43.1)	6	(2.5)	1.00
Clinical findings									
Mucositis/stomatitis	104	(43.0)	4	(1.7)	128	(53.6)	7	(2.9)	0.38
Anorexia	149	(61.6)	16	(6.6)	143	(59.8)	16	(6.7)	1.00
Nausea	119	(49.2)	9	(3.7)	136	(56.9)	8	(3.3)	1.00
Vomiting	37	(15.3)	4	(1.7)	59	(24.7)	5	(2.1)	0.75
Diarrhea	109	(45.0)	16	(6.6)	149	(62.3)	32	(13.4)	0.02
Rash/desquamation	39	(16.1)	1	(0.4)	50	(20.9)	0	(0.0)	1.00
Hyperpigmentation	99	(40.9)	–	–	100	(41.8)	–	–	–
Hand–foot syndrome	125	(51.7)	15	(6.2)	59	(24.7)	2	(0.8)	<0.01
Fatigue	149	(61.6)	12	(5.0)	142	(59.4)	9	(3.8)	0.66
Peripheral sensory neuropathy	223	(92.1)	53	(21.9)	47	(19.7)	0	(0.0)	<0.01
Alopecia	30	(12.4)	–	–	143	(59.8)	–	–	–
Watery eye	2	(0.8)	0	(0.0)	18	(7.5)	3	(1.3)	0.12
Hypertension	86	(35.5)	29	(12.0)	76	(31.8)	20	(8.4)	0.23
Paralytic ileus	8	(3.3)	7	(2.9)	2	(0.8)	0	(0.0)	0.02
Febrile neutropenia	0	(0.0)	0	(0.0)	8	(3.3)	8	(3.3)	<0.01
Thromboembolism	5	(2.1)	2	(0.8)	10	(4.2)	9	(3.8)	0.04
Hemorrhage, nose	28	(11.6)	0	(0.0)	40	(16.7)	0	(0.0)	–
Gastrointestinal perforation	3	(1.2)	3	(1.2)	0	(0.0)	0	(0.0)	0.25

<sup>a</sup>Comparison of the frequency of adverse events of grade 3 or higher in the two groups.


AE, adverse events; AST, aspartate aminotransferase; ALT, alanine aminotransferase.

however, this factor may have affected the incidences of diarrhea and neutropenia [13]. We believe that the safety of S-1 and irinotecan plus bevacizumab can be further enhanced by modifying the initial S-1 dosage depending on renal function, modifying the initial irinotecan dosage depending on UGT1A1 gene polymorphism, providing patient education, and appropriately managing adverse events.

Peripheral neuropathy, an adverse event that interferes with daily life, occurred in 92.1% of the patients in the control group. QOL analysis has shown that peripheral neuropathy not only impairs QOL and interferes with daily life, but also renders the continuation of oxaliplatin administration impracticable and affects efficacy. Similar to previous studies using oxaliplatin as first-line treatment of mCRC, the administration period of oxaliplatin in our study was 24 weeks; however, it was possible to continue the administration of irinotecan for up to approximately

40 weeks or up to discontinuation of the study treatment, and we believe that this contributed to the prolongation of TTF and PFS in the experimental group [1].

The median PFS obtained with mFOLFOX6 or CapeOX plus bevacizumab in our study was similar to the median PFS of approximately 10–11 months obtained in a previous study of fluoropyrimidine and oxaliplatin plus bevacizumab [1, 2]; however, the reported median PFS in that study of fluoropyrimidine and irinotecan plus bevacizumab was 1.5 months longer than the median PFS obtained with fluoropyrimidine and oxaliplatin plus bevacizumab (HR approximately 0.9); moreover, in our study the median PFS obtained with S-1 and irinotecan plus bevacizumab was longer by 3.2 months (HR = 0.84) [14]. These results suggest that the combination regimen of S-1 and irinotecan plus bevacizumab can be an effective first-line treatment of mCRC.



**Figure 2.** Quality of life assessed by (A) FACT-C TOI and (B) FACT/GOG-Ntx. The line on the graph is a straight line drawn from average values using a mixed-effects model. FACT-C TOI, the Functional Assessment of Cancer Therapy-Colorectal Trial Outcome Index scale; FACT/GOG-Ntx, the neurotoxicity subscale of the FACT/Gynecology Oncology Group-Neurotoxicity.

PFS was found to have an interaction with age in our study. Although an interaction was not demonstrated, patients given S-1 and irinotecan plus bevacizumab who had a CCR of 70 ml/min or higher at enrollment tended to have favorable results. It is therefore possible that elderly patients with decreased renal function did not receive sufficient S-1 because of adverse events. On the other hand, non-elderly patients might benefit from aggressive S-1 and irinotecan plus bevacizumab regimens.

About 53.5% of patients who initially receive S-1 (an oral fluoropyrimidine) and irinotecan plus bevacizumab regimens are also given oral fluoropyrimidines as second-line chemotherapy; first-line and second-line treatments for mCRC given orally and without the use of central venous ports are considered very beneficial for both patients and medical practitioners.

Our study had several limitations. The benefit of using S-1 and irinotecan plus bevacizumab as compared with FOLFIRI plus bevacizumab as first-line therapy for mCRC was not confirmed, because we conducted a comparative phase III study in which the most commonly used regimen, namely mFOLFOX6 or CapeOX plus bevacizumab, was given to the control group. However, the noninferiority of S-1 and irinotecan to FOLFIRI as second-line therapy has already been demonstrated [7]. Furthermore, the median PFS (14.0 months) obtained with S-1 and irinotecan plus

bevacizumab in our study is longer than in that in any previous randomized controlled trial and compares favorably not only with the results obtained in the control arm of FOLFIRI plus bevacizumab in TRIBE (9.7 months), but also with the results obtained in the trial arm of FOLFOXIRI plus bevacizumab (12.1 months). Another potential limitation is that we do not know whether our results can be simply extrapolated to a Western population, because the pharmacokinetics and pharmacodynamics of S-1 might vary, and the approved dose of irinotecan (150 mg/m<sup>2</sup>, every 2 weeks) in Japan is lower than that in Western countries. If S-1 combined with irinotecan plus bevacizumab is used as chemotherapy in Western patients, the dose should be carefully adjusted.

## Conclusion

In conclusion, we consider S-1 and irinotecan plus bevacizumab to be an effective first-line therapy for mCRC and believe that it can be included as one of the recommended standard regimens.

## Acknowledgements

We thank all the patients, their families, the investigators, and the medical staff; we thank Yuh Sakata, Hiroyuki Uetake, and



Wasaburo Koizumi for the data and safety monitoring; we also thank Rei Goto as the advisor on medical economics. A list of participating institutions is given in the online [supplementary Appendix S1](#), available at *Annals of Oncology* online.

## Funding

Tokyo Cooperative Oncology Group with funding from Taiho Pharmaceutical Co. Ltd., Japan (no grant number applies) under the study contract.

## Disclosure

YY has received honoraria from Taiho, Chugai, and Yakult. MG has received honoraria from Taiho, Chugai, Yakult, Ono, Shionogi, Nippon Kayaku, and Eli Lilly. HS has received honoraria from Taiho, Eisai, Bayer, Chugai, Eli Lilly, and Yakult and research grants from Taiho, Eisai, and Bayer. AS has received honoraria from Taiho, Chugai, and Yakult and research grants from Taiho and Chugai. SM has received honoraria from Taiho, Chugai, and Daichi-Sankyo. ST has received honoraria from Merck Serono, Taiho, Asahi Kasei, Daichi-Sankyo, Medicon, Novartis, and Mochida and research grants from Merck Serono. YK has received honoraria from Taiho, Eli Lilly, Chugai, Novartis, Bayer, Merck Serono, Pfizer, Yakult, and Daichi-Sankyo and research grants from Taiho, Eli Lilly, MSD, Ono, Chugai, Novartis, Bayer, Yakult, and Daichi-Sankyo. CI has received honoraria from Taiho, Merck Serono, Mochida, Chugai, Daichi-Sankyo, Ono, Takeda, Novartis, Nippon Kayaku, Bayer, and Eli Lilly and research grants from Taiho, Merck Serono, Mochida, Chugai, Daichi-Sankyo, Yakult, Ono, Takeda, Kyowa Hakko Kirin, Eisai, Tsumura, Novartis, Nippon Kayaku, Astellas, Asahi Kasei, Kissei, and Bristol-Myers. All remaining authors have declared no conflicts of interest.

## References

1. Yamazaki K, Nagase M, Tamagawa H et al. Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G). *Ann Oncol* 2016; 27(8): 1539–1546.
2. Cassidy J, Clarke S, Diaz-Rubio E et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. *J Clin Oncol* 2008; 26(12): 2006–2012.
3. André T, Boni C, Navarro M et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. *J Clin Oncol* 2009; 27(19): 3109–3116.
4. Fuchs CS, Marshall J, Mitchell E et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. *J Clin Oncol* 2007; 25(30): 4779–4786.
5. Satoh T, Sakata Y. S-1 for the treatment of gastrointestinal cancer. *Expert Opin Pharmacother* 2012; 13(13): 1943–1959.
6. Muro K, Boku N, Shimada Y et al. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). *Lancet Oncol* 2010; 11(9): 853–860.
7. Schmoll HJ, Van Cutsem E, Stein A et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer: a personalized approach to clinical decision making. *Ann Oncol* 2012; 23(10): 2479–2516.
8. Yamada Y, Yamaguchi T, Matsumoto H et al. Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer. *Invest New Drugs* 2012; 30(4): 1690–1696.
9. Komatsu Y, Yuki S, Sogabe S et al. Phase II study of combined chemotherapy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer. *Acta Oncol* 2012; 51(7): 867–872.
10. Komatsu Y, Ishioka C, Shimada K et al. Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer. *BMC Cancer* 2015; 15(1): 626.
11. Heinemann V, von Weikersthal LF, Decker T et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. *Lancet Oncol* 2014; 15(10): 1065–1075.
12. Loupakis F, Cremolini C, Masi G et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. *N Engl J Med* 2014; 371(17): 1609–1618.
13. Minami H, Sai K, Saeki M et al. Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1\*6 and \*28. *Pharmacogenet Genomics* 2007; 17(7): 497–504.
14. Schmiegel W, Reinacher-Schick A, Arnold D et al. Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group. *Ann Oncol* 2013; 24(6): 1580–1587.